KKKevinkumar Kansagra

Kevinkumar Kansagra

*This is an algorithmically generated author record based on publicly available information.

Kevinkumar Kansagra has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Phase IIa , Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof‐of‐Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell Disease

    by Mohit Desai, Bhargav Solanki, Manish Hathila, Vikas Asati, Suchi Shah, Deven Parmar, Sanjay Vekariya, Kevinkumar Kansagra, Mayank Gangwar, Gunjan Kumar, et al.

    Introduction: Sickle cell disease (SCD) is an inherited hemoglobin disorder caused by a point mutation in the β ‐globin gene, producing hemoglobin S (HbS). Under hypoxic conditions, HbS polymerizes, leading to rigid, sickled erythrocytes with reduced deformability and increased endothelial adhesion, resulting in vaso‐occlusion and impaired tissue perfusion. Desidustat, a hypoxia‐inducible factor prolyl hydroxylase inhibitor, stabilizes HIF and enhances endogenous erythropoietin production. This Phase IIa study evaluated its efficacy and safety in SCD. Methods: Twenty‐four Indian adults with confirmed SCD (Hb 7–11 g/dL for males, 6.5–11 g/dL for females) were enrolled. Patients were randomized (3:1) across three cohorts receiving 50 mg, 100 mg, or 150 mg desidustat, or placebo, thrice weekly for 8 weeks. The primary endpoint was the proportion achieving ≥ 1 g/dL hemoglobin increase from baseline to Week 8. Secondary endpoints included changes in hemoglobin, hemolysis biomarkers, HbS percentage, transfusion requirement, and vaso‐occlusive events. Safety was assessed via adverse events and clinical parameters. Results: Among 24 patients (10 males, 14 females; age 25–38 years), Hb response was observed in 50% of patients in the 150 mg cohort versus 16.7% in placebo. Hemoglobin increased dose‐dependently, with reduced LDH levels. No significant changes were noted in HbS or most hemolysis markers. No transfusions or vaso‐occlusive crises occurred. Reported adverse events were mild (nasopharyngitis, polyarthritis, headache), non‐serious, and unrelated to treatment. Conclusion: Desidustat was well tolerated, with the 150 mg dose showing promising improvements in hemoglobin levels and response rates in SCD patients. Trial Registration: CTRI/2024/06/068363

  • Open Access

    Phase 3, Randomized, Non-Inferiority Trial Comparing a Novel Vilanterol, Umeclidinium and Fluticasone Furoate Fixed Dose Combination Dry Powder Inhaler with Indacaterol, Glycopyrronium and Mometasone Furoate Fixed Dose Combination Dry Powder Inhaler in Indian Patients with Asthma

    by Pankaj Vyas, Mitul Chaudhari, Jaydip Deb, Amit Bhate, Manish Jain, Akash Balki, Ram Kaulgud, Abhay Javia, Deven Parmar, Kevinkumar Kansagra, et al.

    Background A novel fixed-dose combination of vilanterol 25-µg, umeclidinium 62.5-µg, and fluticasone furoate 200-µg (VIL-UME-FF) in dry powder inhaler (DPI) was developed by M/s. Zydus Healthcare Limited for managing persistent asthma. Methods In this phase 3, multicenter, parallel group, open-label, randomized trial, patients received either test (VIL-UME-FF DPI) or reference DPI (indacaterol 150-µg, glycopyrronium 50-µg, and mometasone furoate 160-µg; IND-GLY-MF DPI). The primary endpoint was change from baseline in trough forced expiratory volume-1 (FEV1) at week-12. Secondary endpoints included trough forced vital capacity (FVC), post-bronchodilator FEV1 and FVC, and asthma control test (ACT) score. Results A total of 258 participants (18-65 years) were enrolled (Test: 129; Reference: 129). The least square mean change in trough FEV1 at week-12 was 342.9 (21.3) ml for the test group and 327.6 (21.4) ml for the reference group (p=0.6141). The lower limit of 95% confidence interval for the difference between the groups was -44.19 ml, well-above the predefined non-inferiority margin (-150 ml). At week-12, trough FVC, post-bronchodilator FEV1 and FVC, and ACT scores were comparable between the study groups. Conclusion VIL-UME-FF DPI was non-inferior to IND-GLY-MF DPI in improving trough FEV1 and other efficacy parameters and was well-tolerated in Indian patients with persistent asthma.

  • Open Access

    Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus

    by Prabhat Kumar Sharma, V. Viswaprasad, Animesh Choudhary, Ansari Rizwanahmed Nurulhasan, Sagar Vivek Redkar, Patel Manan Bharatkumar, Vijaykumar Shivajirao Patil, Sumit Anand, Vijaykumar Barge, Shalin J. Shah, et al.

  • Open Access

    Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial

    by Prabhat Kumar Sharma, Sagar Vivek Redkar, Abhishek Madhav Karmalkar, Sumit Anand, Vijaykumar Shivajirao Patil, Ansari Rizwanahmed Nurulhasan, Patel Manan Bharatkumar, Vijaykumar Barge, Shalin J. Shah, Chintan B. Patel, et al.


  • Open Access

    Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants

    by Songa Narayana Rao, Deepali Ambike, Mahantesh Patil, Sanjay Vasant Mankar, Nishant Verma, Neeta Hanumante, Lisa Sarangi, Monjori Mitra, Godatwar Preeti, Bhaskar Jedhe Deshmukh, et al.

    Typhoid fever, measles, and rubella continue to contribute significantly to childhood morbidity and mortality in India. In line with WHO recommendations for co-administration of Typhoid Conjugate Vaccine (TCV) and measles–rubella (MR) vaccine at 9 months of age, this phase IV, randomized, open-label, multicenter clinical trial was conducted to assess their immunological compatibility and safety when administered concomitantly. A total of 900 healthy Indian infants aged 9–10 months were randomized into three groups: Group A received TCV and MR vaccine concomitantly; Group B received MR on Day 0 and TCV on Day 28; Group C received TCV on Day 0 and MR on Day 28. Subjects were followed for 6 months after concomitant/last vaccination. Seroconversion rates (SC) in Groups A/B/C at Day 28 were 90.2%/75.3%/89.5% for anti-Vi; 80.4%/75.2%/77.7% for anti-measles, and 87.7%/84.0%/85.2% for anti-rubella antibodies. By study end, SC for anti-Vi was 87.1%/71.6%/83.0%, while SC for anti-measles and anti-rubella reached ~90% and ≥98%, respectively, across all groups. Geometric mean titers increased significantly for all antigens, with no evidence of immunological interference. Safety assessments showed adverse events in 23.9%/32.0%/32.7% participants in Group A/B/C. Most adverse events were mild, and only one serious adverse event was reported. These findings support the co-administration of TCV and MR vaccine as a safe and effective strategy.

  • Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants

    by Kevinkumar A. Kansagra, Taufik Momin, Hardik B. Patel, Chintan Shah, Gordhan Parmar, Ashok Ghoghari, Harilal V. Patel, Deven V. Parmar

    To perform first-in-human single-dose escalation trial of ZYKR1, which is a potent, selective, and peripherally-restricted kappa opioid receptor agonist, is the purpose of this study. This randomized, double-blind, placebo-controlled single ascending dose study conducted at Zydus Research Centre, Ahmedabad, India included healthy male participants aged 18–55 years and weighing > 50 kg. The primary objective was to evaluate the safety and tolerability of ZYKR1. The secondary objective was to evaluate the pharmacokinetics and pharmacodynamics (PD) of ZYKR1. Participants received ZYKR1 (0.5 − 6 mcg/kg) or placebo infused intravenously in 15 ± 1 min. Of total five dose groups (0.5 − 6 mcg/kg), each group included eight participants with six and two randomized to ZYKR1 and placebo, respectively. Three participants experienced six treatment-emergent adverse events (TEAEs); two were gastrointestinal disorders (nausea and vomiting at 2 mcg/kg); and four were related to the nervous system (headache (at 2 mcg/kg) and facial tingling, facial numbness and paresthesia (at 6 mcg/kg)); all TEAEs were mild and resolved without sequelae. The Cmax of ZYKR1 was achieved after 15 − 20 min of start of infusion. The mean exposures (Cmax and AUC0 − t) increased in a dose-proportional manner. The mean t1/2 ranged from 2.20 to 2.98 h across the dose range. Increase in the mean prolactin level was significantly higher in treatment groups compared with that in the placebo group. Intravenous ZYKR1 at doses up to 6 mcg/kg showed acceptable safety and tolerability and demonstrated a short half-life with principal route of excretion as renal. ZYKR1 displayed a potent PD effect reflected by increased prolactin levels, supporting further study in patients. Trial registration Clinical Trial Registry of India: CTRI/2018/07/014927. Date of registration: 18/07/2018.


  • Open Access

    Safety, Tolerability and Pharmacokinetics ofNovel Triaminopyrimidine ZY-19489: A Randomised Double-blind Placebo-control Phase-1 Study among Healthy Indian Participants

    by Zydus Lifesciences Limited Clinical R&D, Kevinkumar Kansagra

    Background: ZY-19489 is a triaminopyrimidine comprising the novel antimalarial class. Methods: This was a phase-1, two-part double-blind, placebo-controlled study conducted in Ahmedabad, India. Part-1 was a single-dose singlecohort study. Part-2 was a multiple-ascending-dose study. Healthy participants aged 18-55 years were included. The primary objective was to evaluate the safety and tolerability of ZY-19489 in healthy adult Indian participants. This study was registered with CTRI/2021/08/035449 and on clinicaltrials.gov (NCT05206201). Findings: Eight participants were enrolled in part-1 (450 mg) and 16 participants were enrolled in part-2, a multiple ascending dose part, (two cohorts; 300 and 500 mg once daily for three days). All participants were randomised to a 3:1 ratio (ZY-19489:placebo) within the cohort. The majority of adverse events (AEs) reported were mild in severity. One of six participants in part-1 and one of twelve participants in part-2, exposed to ZY-19489, experienced grade-2 AEs (enteric fever, dengue, and leg pain). One of six participants in part-1 and one of twelve participants in part-2, exposed to ZY-19489, experienced grade-3 AEs (GGT increase and epigastric pain). Following single-dose administration, ZY-19489 displayed slow oral absorption with a median Tmax of 7.5 h and a mean elimination half-life of 90 h. Following multiple dose administration of ZY-19489 for three consecutive days, on day 3, the maximum plasma concentration was achieved at 6.25 h (median Tmax) after dosing. Conclusion: ZY-19489 was well-tolerated up to 500 mg once a day for three days. It displayed good oral absorption, dose-proportional increase in exposure, and long elimination half-life. How to cite this article:Kansagra KA, Patel HB, Jansari GA, Momin T, Ghoghari A, Barot A, Patel HV. Safety, Tolerability and Pharmacokinetics of a Novel Triaminopyrimidine ZY-19489: A Randomised Double-blind Placebo-control Phase-1 Study among Healthy Indian Participants. J Commun Dis. 2023;55(2):53-66. DOI: https://doi.org/10.24321/0019.5138.202325

  • A Food‐Effect Study to Evaluate the Oral Bioavailability of Desidustat

    by Hardik Patel, Taufik Momin, Kevinkumar Kansagra, Harilal Patel, Chintan Shah, Ajaykumar Barot, Jay Bhavsar, Kuldipsinh Zala, Deven Parmar

  • Open Access

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

    by Deven V. Parmar, Kevinkumar A. Kansagra, Taufik Momin, Hardik B. Patel, Gaurav A. Jansari, Jay Bhavsar, Chintan Shah, Jayesh M. Patel, Ashok Ghoghari, Ajay Barot, et al.

    ZYIL1 is a nucleotide‐binding oligomerization domain, leucine rich repeat and pyrin domain‐containing 3 (NLRP3) inflammasome inhibitor, which prevents NLRP3‐induced apoptosis‐associated speck‐like protein containing a caspase activation and recruitment domain oligomerization, thus inhibiting NLRP3 inflammasome pathway. We investigated the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ZYIL1 after single and multiple doses in healthy subjects. The subjects aged 18–55 years were enrolled in 2 different studies: single and multiple ascending dose. Blood/urine samples were collected at designated time points for pharmacokinetic and pharmacodynamic analysis. In the single‐ascending‐dose study, 30 subjects were enrolled (6 subjects each in 5 dose groups). One adverse event was reported during the study. ZYIL1 was well absorbed with median time to maximum plasma concentration at 1–1.5 hours. The exposures were dose proportional across the dose ranges. ZYIL1 is excreted as an unchanged form via the renal route. The mean elimination half‐life was 6–7 hours. In the multiple‐ascending‐dose study, 18 subjects were enrolled (6 subjects each in 3 dose groups). Eleven adverse events were reported by 6 subjects during the study. The accumulation index at steady state for area under the plasma concentration–time curve indicated that ZYIL1 has a marginal accumulation upon repeated dosing. Dose‐proportional exposure was observed across the dose ranges. All subjects showed >90% interleukin (IL)‐1β inhibition in all dose groups for both studies. Inhibition in IL‐1β and IL‐18 was observed throughout the 14 days of treatment in the multiple‐dose study. The safety profile, rapid absorption, marginal accumulation, and significant inhibition of IL‐1β and IL‐18 level support its development for the management of inflammatory disorders.